This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (22)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neuropathology  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Thomas Müller, MD; Kathrin Renger, MD; Wilfried Kuhn, MD

Arch Neurol. 2004;61:657-660.

Background  Levodopa metabolism via catechol O-methyltransferase increases levels of the neurotoxin homocysteine, which induces an axonal-accentuated degeneration in sensory peripheral nerves in vitro.

Objectives  To demonstrate associations among daily levodopa/dopa decarboxylase inhibitor intake, total homocysteine plasma (tHcy) levels, and electrophysiologic sural nerve conduction findings.

Design  We performed bilateral assessment of sensory nerve conduction velocity and sensory nerve action potentials and determined tHcy levels.

Patients  Thirty-one levodopa-treated patients with Parkinson disease (PD) and 27 control subjects.

Results  Sensory nerve action potentials significantly (P<.001) differed between PD patients and controls. No differences between sensory nerve conduction velocities of PD patients and controls appeared. We found significant differences in sensory nerve action potentials be-tween PD patients with significantly elevated tHcy levels and controls (P<.001), PD patients with tHcy levels within the reference range and those with elevated levels (P = .001), and PD patients with tHcy levels levels within the reference range and and controls (P = .04). Our sensory nerve conduction velocity results showed no significant differences. There were significant associations between tHcy levels and sensory nerve action potentials (R = –0.52; P = .002) and and sensory nerve conduction velocity (R = –0.47; P = .008). Daily levodopa/dopa decarboxylase inhibitor intake was significantly related to tHcy levels (R = 0.43; P = .02).

Conclusions  This electrophysiological sign of peripheral neuronal dysfunction may be circumstantial evidence suggesting that, to a certain extent, sensory nerve action potentials are a surrogate marker for the levodopa metabolism–induced elevation of homocysteine levels and the aggravation of the ongoing central neurodegenerative process.

From the Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany. Dr Kuhn is now with the Department of Neurology, Leopoldina Krankenhaus, Schweinfurt, Germany.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Levodopa Elevates Homocysteine: Is This a Problem?
Padraig O'Suilleabhain and Ramon Diaz-Arrastia
Arch Neurol. 2004;61(5):633-634.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Methylation Status and Neurodegenerative Markers in Parkinson Disease
Obeid et al.
Clin. Chem. 2009;55:1852-1860.
ABSTRACT | FULL TEXT  

Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation
Nolano et al.
Brain 2008;131:1903-1911.
ABSTRACT | FULL TEXT  

Levodopa Elevates Homocysteine: Is This a Problem?
O'Suilleabhain and Diaz-Arrastia
Arch Neurol 2004;61:633-634.
FULL TEXT